Main

Pedro Romero, MD

Håkan Mellstedt, MD, PhD

David Carbone, MD, PhD

David Jablons, MD

Charles A. Butts, MD

Summary

Summary

DR. BONOMI: We have learned that targeted therapies for cancer appear to provide a kinder, gentler, more patient-specific approach. Vaccines meet those criteria. In the years to come, we can expect cancer vaccine strategies to evolve continuously and we can anticipate that they will afford another important therapeutic option for patients.

What’s Next in Cancer Vaccine Development?

• Further optimization of vaccines

• Long-term memory induction

• Overcoming negative regulators of the adaptive immune response

• Overcoming tumor microenvironment factors that dampen the specific T-cell response

Source: Pedro Romero, MD

A PDF reprint of the InFocus Discussion Highlights is available for download. Click for full DOWNLOAD listing.

Moderator

Philip Bonomi, MD

Director, Section of Medical Oncology
Alice Wirtz Professor of Medicine
Rush-Presbyterian St. Luke’s Medical Center
Chicago, Illinois

<<

Philip Bonomi, MD

>>

Click to proceed through discussion highlights

Discussion Highlights

Rationale for Vaccine Therapy in Cancer Patients

Pedro Romero, MD

Vaccine Development for GI and Hematologic Malignancies

Håkan Mellstedt, MD, PhD

Overview of Lung Cancer Vaccines

David Carbone, MD, PhD

Gene-based Vaccine Therapy in NSCLC

David Jablons, MD

Development of L-BLP25 Vaccine for NSCLC

Charles A. Butts, MD

Summary

Philip Bonomi, MD

Roundtable Discussion

Streaming audio:

Moderator, Philip Bonomi, MD, leads summary of InFocus Roundtable discussion.

Media may not be viewable without Macromedia Flash Player. Version 6.0 or higher is required. If needed, Macromedia Flash Player 8.x is available for free download from www.macromedia.com.